Literature DB >> 9175740

The telomere lengthening mechanism in telomerase-negative immortal human cells does not involve the telomerase RNA subunit.

T M Bryan1, L Marusic, S Bacchetti, M Namba, R R Reddel.   

Abstract

According to the telomere hypothesis of senescence, the progressive shortening of telomeres that occurs upon division of normal somatic cells eventually leads to cellular senescence. The immortalisation of human cells is associated with the acquisition of a telomere maintenance mechanism which is usually dependent upon expression of the enzyme telomerase. About one third of in vitro immortalised human cell lines, however, have no detectable telomerase but contain telomeres that are abnormally long. The nature of the alternative telomere maintenance mechanism (referred to as ALT, for Alternative Lengthening of Telomeres) that must exist in these telomerase-negative cells has not been elucidated. It has previously been shown that abnormal lengthening of yeast telomeres may occur due to mutations in the yeast telomerase RNA gene. That this is not the mechanism of the abnormally long telomeres in ALT cell lines was demonstrated by the finding that seven of seven ALT lines have wild-type human telomerase RNA (hTR) sequence, including a novel polymorphism that is present in 30% of normal individuals. We found that two ALT cell lines have no detectable expression of the hTR gene. This shows that the ALT mechanism in these cell lines is not dependent on hTR. Expression of exogenous hTR via infection of these cells with a recombinant hTR-adenovirus vector did not result in telomerase activity, indicating that their lack of telomerase activity is not due to absence of hTR expression. We conclude that the ALT mechanism is not dependent on the expression of hTR, and does not involve mutations in the hTR sequence.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9175740     DOI: 10.1093/hmg/6.6.921

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  55 in total

1.  Telomere maintenance in telomerase-deficient mouse embryonic stem cells: characterization of an amplified telomeric DNA.

Authors:  H Niida; Y Shinkai; M P Hande; T Matsumoto; S Takehara; M Tachibana; M Oshimura; P M Lansdorp; Y Furuichi
Journal:  Mol Cell Biol       Date:  2000-06       Impact factor: 4.272

2.  The hTERTalpha splice variant is a dominant negative inhibitor of telomerase activity.

Authors:  L M Colgin; C Wilkinson; A Englezou; A Kilian; M O Robinson; R R Reddel
Journal:  Neoplasia       Date:  2000 Sep-Oct       Impact factor: 5.715

3.  Polymerization defects within human telomerase are distinct from telomerase RNA and TEP1 binding.

Authors:  T L Beattie; W Zhou; M O Robinson; L Harrington
Journal:  Mol Biol Cell       Date:  2000-10       Impact factor: 4.138

4.  Activation of p53 protein by telomeric (TTAGGG)n repeats.

Authors:  M Milyavsky; A Mimran; S Senderovich; I Zurer; N Erez; I Shats; N Goldfinger; I Cohen; V Rotter
Journal:  Nucleic Acids Res       Date:  2001-12-15       Impact factor: 16.971

5.  Telomere length assessment in human archival tissues: combined telomere fluorescence in situ hybridization and immunostaining.

Authors:  Alan K Meeker; Wesley R Gage; Jessica L Hicks; Inpakala Simon; Jonathan R Coffman; Elizabeth A Platz; Gerrun E March; Angelo M De Marzo
Journal:  Am J Pathol       Date:  2002-04       Impact factor: 4.307

6.  Impaired germinal center reaction in mice with short telomeres.

Authors:  E Herrera; C Martínez-A; M A Blasco
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

7.  Modification of subtelomeric DNA.

Authors:  Susanne Steinert; Jerry W Shay; Woodring E Wright
Journal:  Mol Cell Biol       Date:  2004-05       Impact factor: 4.272

8.  Pilocytic astrocytomas have telomere-associated promyelocytic leukemia bodies without alternatively lengthened telomeres.

Authors:  Tania Slatter; Jennifer Gifford-Garner; Anna Wiles; Xin Tan; Yu-Jen Chen; Martin MacFarlane; Michael Sullivan; Janice Royds; Noelyn Hung
Journal:  Am J Pathol       Date:  2010-10-29       Impact factor: 4.307

9.  N-terminal domains of the human telomerase catalytic subunit required for enzyme activity in vivo.

Authors:  B N Armbruster; S S Banik; C Guo; A C Smith; C M Counter
Journal:  Mol Cell Biol       Date:  2001-11       Impact factor: 4.272

10.  Telomerase reverse transcriptase is required for the localization of telomerase RNA to cajal bodies and telomeres in human cancer cells.

Authors:  Rebecca L Tomlinson; Eladio B Abreu; Tania Ziegler; Hinh Ly; Christopher M Counter; Rebecca M Terns; Michael P Terns
Journal:  Mol Biol Cell       Date:  2008-06-18       Impact factor: 4.138

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.